Study reveals a detailed map of gene proteins, infiltrating cells, and signaling pathways that play significant roles in the development and progression of glioblastoma brain cancer.
Inhibiting the SCD enzyme and blocking the function of FOSB blunts acquired drug resistance and improves survival in mouse models of glioblastoma brain cancer.
Researchers have identified a pathway involving a protein called Rab35 in glioblastoma brain cancer. The study reports restoring the activity of Rab35 could have therapeutic benefits for those with glioblastoma.
20% of glioblastoma brain cancers are fueled by overactive mitochondria. Researchers say these cases may be treatable by drugs currently under trial.
Study reports brain tumors may arise when damaged brain tissue does not heal correctly. Researchers say some glioblastoma form when the normal healing process gets derailed by mutations. This process could begin many years before patients become symptomatic of brain cancer.
Loperamide, an anti-diarrhea medication, induces autophagy in glioblastoma brain cancer cells.
Researchers have identified a cancer-causing mutation in the PDGFRA gene that drives cell mutation and growth when activated. The findings have implications for the treatment of a subset of glioblastoma brain cancer.
Increased YTHDF3 expression appears to be a key driver in brain metastases.
MP-Pt(IV), a second generation prodrug appears to have curative properties against glioblastoma when coupled with chemotherapy in mouse models.
Study reveals how two key molecules, Rab27b, and epiregulin, interact to contribute to radioresistance in glioblastoma brain cancer.
Mouse study reveals the deletion of the OSMR gene significantly improves glioblastoma tumor response to therapy and extended lifespan.
Glioblastoma brain cancer cells that are more resistant to radiation therapy have higher levels of purines. Reducing the level of purines made the cancer cells more sensitive to radiation.
